EyePoint, Inc. (EYPT)

EyePoint Pharmaceuticals' stock has been influenced by several key events in the past six months. The company reported its Q2 2025 earnings in August 2025, with total net revenue decreasing to $5.3 million, and Q3 2025 revenue of $966,000, missing expectations. In January 2026, EyePoint announced that its Phase 3 clinical trials for DURAVYU in wet AMD are progressing towards data readouts expected to begin in mid-2026. Over the past six months, EyePoint insiders have primarily sold shares. Multiple analysts have issued price targets for EYPT, with a median target of $27.0 in the last six months. In December 2025, EyePoint Pharmaceuticals, Inc. officially changed its corporate name to EyePoint, Inc. The stock price has shown volatility but has seen a significant increase of 101.38% from January 6, 2025, to January 2, 2026.

No specific information regarding demand seasonality for EyePoint Pharmaceuticals' products and services was found in the available search results.

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic therapies for serious eye conditions, utilizing sustained-release drug delivery technologies. Its commercial products include DEXYCU® and YUTIQ®, and its lead pipeline candidate is DURAVYU (EYP-1901), which is in Phase 3 clinical trials for wet AMD and DME. The company has shifted its focus to clinical-stage development, emphasizing its EYP-1901 program.

EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts, with additional offices in Basking Ridge, New Jersey. Clinical trials for DURAVYU in wet AMD have included patient enrollment across both U.S. and international sites.

EyePoint Pharmaceuticals' reputation was impacted in July 2024 when the FDA issued a warning letter to its Watertown, Massachusetts facility, following a Form 483 issued in March 2024. The FDA's citations highlighted several manufacturing issues related to Yutiq, including batch inconsistencies and inadequate written procedures. EyePoint stated its commitment to resolving all FDA observations and implementing corrective actions, assuring that these issues were confined to Yutiq's manufacturing and would not impact other products in development like DURAVYU.

EyePoint Pharmaceuticals' ownership is a mix of institutional, insider, and retail investors. Approximately 65.06% of the company's stock is owned by institutional investors, 10.72% by insiders, and 24.22% by public companies and individual investors. Major institutional owners include Cormorant Asset Management, LP, Suvretta Capital Management LLC, Adage Capital Partners GP LLC, BlackRock, Inc., Federated Hermes Inc., Franklin Resources Inc., and Vanguard Group Inc. EW Healthcare Partners LP is noted as the largest individual shareholder, owning 87.30 million shares.